| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | GSK1059615 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.02 |
| mRNA | MLN2238 | CTRPv2 | pan-cancer | AAC | 0.082 | 0.02 |
| mRNA | tacedinaline | CTRPv2 | pan-cancer | AAC | -0.091 | 0.02 |
| mRNA | PD-0325901 | gCSI | pan-cancer | AAC | 0.12 | 0.02 |
| mRNA | LY-2183240 | CTRPv2 | pan-cancer | AAC | 0.073 | 0.02 |
| mRNA | FK866 | CTRPv2 | pan-cancer | AAC | 0.087 | 0.02 |
| mRNA | UNC0638:navitoclax (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.083 | 0.02 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | -0.083 | 0.02 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | -0.1 | 0.03 |
| mRNA | Obatoclax Mesylate | CTRPv2 | pan-cancer | AAC | 0.075 | 0.03 |